HOPEWELL, N.J., August 04, 2021--(BUSINESS WIRE)--Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that management will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021. The details are as follows:
Event: 2021 Wedbush PacGrow Healthcare Conference
Panel: So Let it Be (Re)Written - Updates in Gene Modulation
Date: Tuesday, August 10, 2021
Time: 9:10 AM ET
Members of the Gennao Bio management team will also host investor meetings during the conference.
A live webcast of the panel discussion will be available on the company’s website at www.gennao.com. A replay of the webcast will also be available for 30 days shortly after the conclusion of the event.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005077/en/
Investor and Media Contact: